Skip to main content
. 2017 Mar 10;8(19):31169–31179. doi: 10.18632/oncotarget.16099

Figure 2.

Figure 2

Time-dependent receiver operating characteristics curves of DpR and ETS for progression-free survival at 6.7 months* (A) and overall survival at 13.8 months* (C); time-dependent integrated AUC of DpR and ETS for progression-free survival (B) and overall survival (D). *6.7 months and 13.8 months were chosen from median progression-free survival and median overall survival data reported for the Trastuzumab for Gastric Cancer (ToGA) trial. AUC, area under the curve; ETS, early tumor shrinkage; DpR, depth of response.